CX3CR1 and neoplasm: Combining scRNA/TCR-seq of sorted T cells in serial PB samples with TCR-seq of tumor tissue provided insight into the transcriptional landscape of circulating TIL-TCRs, and revealed that expanded circulating TIL-TCRs early on-treatment were enriched in signatures of terminal effector differentiation and marked by high expression of CX3CR1.